Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$120.99M$120.99Mderived+26.5% vs Q4 2024 Net Income-$17.67M-$17.67MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$84,268,000+27.3% Operating Incomederived-$14,235,000N/M Operating Cash Flowderived-$3,090,000N/M Free Cash Flowderived-$7,437,000N/M Margins · derivedGross margin69.6%+0.4 pt vs Q4 2024
Operating margin-11.8%−21.0 pt vs Q4 2024
Net margin-14.6%−20.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 23, 2026 · 54 d after period end